Connexion
Connexion
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Inscription
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NICOX SA.

(COX)
  Rapport
Temps réel Euronext Paris  -  17:35 09/12/2022
1.220 EUR   -1.61%
29/11Nicox : Armistice Capital dépasse les 10% du capital
CF
29/11Nicox : Document AMF CP. 222C2570
PU
23/11Nicox : lève 10 millions d'euros avec un placement privé
AO
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur NICOX SA.
22/11Nicox Falls 5% After Raising $10 Million Via Private Placement
22/11Bolsa de Madrid: Aquí todo es cuesta abajo
22/11Nicox Raises €10 Million in Private Placemen
22/11Nicox Raises €10 Million in Private Placement
22/11Nicox Raises €10 Million in Private Placement
22/11Nicox Raises €10 Million in Private Placemen
07/11Bolsa de Madrid: Precaución, frágil
07/11Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma
07/11Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma
07/11Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma
31/10Nicox's Investigational Once-daily Drug Lowers Eye Pressure in Late-stage Study
31/10Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Tri..
31/10Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Tri..
31/10Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucom..
19/10Nicox Provides Third Quarter 2022 Financial and Business Highlights
19/10Nicox Provides Third Quarter 2022 Financial and Business Highlights
04/10Bolsa de Madrid: El mercado intenta una nueva partitura
19/09Nicox Completes Late-stage Study of Eye Disease Drug
19/09Bolsa de Madrid: Y ¡bang!
19/09Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glauco..
19/09Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glauco..
19/09Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc G..
19/09Nicox S.A.(ENXTPA:COX) dropped from S&P Global BMI Index
16/09Bolsa de Madrid: La sombra de las brujas y la Fed planea sobre los merca..
16/09Nicox Provides First Half 2022 Business Update and Financial Results
16/09Nicox Provides First Half 2022 Business Update and Financial Results
16/09Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
16/09Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
16/08Nicox : Document AMF CP. 2022E857303
03/08Nicox to Participate in Financial and Scientific Events in Q3 2022
03/08Nicox to Participate in Financial and Scientific Events in Q3 2022
29/07Ophthalmology Group Nicox Names Permanent Chairman
29/07Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors
29/07Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors
29/07Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors
20/07Nicox Provides Second Quarter 2022 Financial and Business Highlights
20/07Nicox Provides Second Quarter 2022 Financial and Business Highlights
08/07Nicox : 2022 Extraordinary Shareholder Meeting
08/07Nicox : 2022 Extraordinary Shareholder Meeting
07/07Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hem..
07/07Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hem..
07/07Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hem..
05/07Nicox : Half-year liquidity contract statement for NICOX
05/07Nicox : Half-year liquidity contract statement for NICOX
22/06Nicox Extraordinary General Meeting of July 11, 2022
22/06Nicox Extraordinary General Meeting of July 11, 2022
15/06Nicox : Suggested agenda and summary of the resolutions submitted to the approval of the E..
15/06Nicox : How to participate in the Extraordinary shareholder meeting
14/06Nicox : 2022 Ordinary Shareholder Meeting
14/06Nicox : 2022 Ordinary Shareholder Meeting
03/06Nicox : 2022 Extraordinary Shareholder Meeting
03/06Nicox : 2022 Extraordinary Shareholder Meeting
03/06Ophthalmology Group Nicox To Release Data From Late-stage Glaucoma Drug Trial In Novemb..
03/06Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov..
03/06Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov..
03/06Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial t..
16/05Ophthalmology Group Nicox Appoints New CEO, Chairman
16/05Nicox Announces a New Governance Structure
16/05Nicox Announces a New Governance Structure
16/05Nicox S.A. Announces Executive Changes
04/05Nicox : 2022 Ordinary Shareholder Meeting
04/05Nicox : 2022 Ordinary Shareholder Meeting
02/05Nicox At Arvo 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
02/05Nicox At Arvo 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
28/04Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Pr..
11/04Nicox's NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma
11/04Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma
03/03Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA ..
03/03Ocumension Therapeutics Says Phase III Study of Eye Drops in China Yields Positive Resu..
02/03Nicox Partner Fera Pharmaceuticals Wins US FDA's Orphan Drug Designation for Sickle Cel..
02/03Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA ..
01/03Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE..
01/03Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZER..
01/03Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE..
23/02Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 C..
23/02Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 C..
22/02France's Nicox Wins Japanese Patent for Dry Eye Disease Drug
22/02Nicox Granted New Patent for NCX 4251 in Japan
21/02Nicox Receives New Chinese Patent For Ocular Hypertension Product
21/02Nicox Granted New Patent for NCX 470 in China, Extending Coverage to 2039
21/02Nicox S.A. Announces Chinese National Intellectual Property Administration Grant A Form..
08/02Nicox to Launch New Dry Eye Disease Study in 2023
08/02Nicox's Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye
08/02Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye
27/01Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 ..
21/01Nicox Provides Fourth Quarter 2021 Business and Financial Highlights
06/01Nicox : Half-year liquidity contract statement for NICOX
05/01Nicox Secures European Patent For Allergic Conjunctivitis Treatment
05/01Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030
2021Nicox Screens First Patient in China in Late-Stage Trial For Glaucoma Treatment
2021Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T..
2021Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T..
2021Global markets live: General Motors, JP Morgan, Pfizer, Novavax, For..
2021Nicox Appoints Novartis Executive as Chief Scientific Officer
2021Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-c..
2021Nicox Appoints Doug Hubatsch as New Chief Scientific Officer to Lead Clinical and Non-C..
2021Opiniones de los analistas del día: Daimler, Relx, As..
2021Bolsa de Madrid: Covid y inflación para terminar la semana
2021Nicox Raises $17 Million in Share Placement, Restructures Kreos Bond Financing Deal
2021Nicox Restructures Kreos Capital Bond Financing Agreement and Raises €15 Million in Pri..